MRT-8102 Phase 1 data show broad normalization of ASCVD drivers, with three Phase 2 trials on the horizon
GLUE sits 86% above its 52-week low of $7.09.
Summary
MRT-8102 showed broad normalization of ASCVD pathogenic drivers in a Phase 1 study, with no safety concerns, and the company plans three Phase 2 trials starting as early as Q4 2026.
Key Events · Product Development and Regulatory · GLUE
-
Phase 1 GFORCE-1 Data Positive
MRT-8102 achieved 80-90% NEK7 degradation across all doses and normalized key ASCVD drivers: calprotectin -56%, S100A12 -46%, SAA -51%, hsCRP -85%, Lp(a) -24%, all to healthy-volunteer levels.
-
Clean Safety Profile
No serious adverse events in 108 subjects; TEAE rates similar to placebo (33% vs 30%); no increased infection risk — a key differentiator vs IL-1/IL-6 biologics.
-
Three Phase 2 Trials Planned
GFORCE-2 (CAD, ~160 patients) in H1 2027; GEMINI-1 (gout, ~60 patients) in Q4 2026/Q1 2027 with data in H2 2027; GALAXY-1 (HS, ~160 patients) in H1 2027.
-
Precision Medicine Opportunity
29% of subjects carry highest-risk NLRP3 GG genotype with significantly higher baseline ASCVD biomarkers, supporting a genetically enrichable patient population for future development.
Analysis · GLUE · Life Sciences
Positive Phase 1 results for MRT-8102, a NEK7-directed molecular glue degrader, point to robust target engagement and broad normalization of key atherosclerotic cardiovascular disease (ASCVD) pathogenic drivers. The drug reduced calprotectin by 56%, S100A12 by 46%, SAA by 51%, hsCRP by 85%, and Lp(a) by 24% — all to healthy-volunteer levels — with no serious adverse events and no increased infection risk. This de-risks a large cardiovascular franchise: the company is advancing into three Phase 2 studies (GFORCE-2 in coronary artery disease, GEMINI-1 in gout, GALAXY-1 in hidradenitis suppurativa) starting as early as Q4 2026. The data also support a precision-medicine approach, with NLRP3 risk-allele carriers showing higher baseline biomarker levels. For a company with a $1B market cap and $626M in cash, this is a meaningful pipeline catalyst that validates the NEK7/NLRP3 mechanism across multiple large indications.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 37.9% of the 895 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.87%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GLUE was trading at $13.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $7.09 to $25.77. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.